JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

Phase 3

Active, not recruiting

Conditions: Urothelial Cancer

Interventions: Drug: Erdafitinib
Drug: Vinflunine
Drug: Pembrolizumab
Device: Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
Drug: Docetaxel

First Posted Date: 2018-01-04

Last Posted Date: 2025-05-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 629

Registration Number: NCT03390504

Locations: 🇫🇷
Hopital de la Timone, Marseille, France
🇩🇪
Asklepios Klinik Altona, Hamburg, Germany
🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany

and more 341 locations

A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy

Phase 2

Completed

Conditions: Leprosy, Multibacillary

Interventions: Drug: Bedaquiline 200 mg

First Posted Date: 2017-12-27

Last Posted Date: 2024-02-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 11

Registration Number: NCT03384641

Locations: 🇧🇷
Instituto Lauro de Souza Lima, Bauru, Brazil
🇧🇷
Fundacao Hospitalar de Dermatologia Tropical e Venereologia Alfredo da Matta - FUHAM, Manaus, Brazil

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Drug: Daratumumab
Drug: Vincristine
Drug: Prednisone
Drug: Doxorubicin
Biological: Peg-asparaginase
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: 6-mercaptopurine
Drug: Methotrexate

First Posted Date: 2017-12-27

Last Posted Date: 2025-05-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 47

Registration Number: NCT03384654

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇩🇪
Universitatsklinikum Munster, Münster, Germany
🇪🇸
Hosp Univ Vall D Hebron, Barcelona, Spain

and more 50 locations

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Phase 3

Terminated

Conditions: Influenza A

Interventions: Drug: Pimodivir 600 mg
Drug: Placebo
Other: SOC Treatment

First Posted Date: 2017-12-21

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 553

Registration Number: NCT03381196

Locations: 🇫🇷
Centre Hospitalier Intercommunal de Créteil, Creteil cedex, France
🇫🇷
Centre Hospitalier Départemental, La Roche S/ Yon Cedex 9, France
🇫🇷
CHU de Grenoble Hopital Albert Michallon, La Tronche, France

and more 418 locations

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: JNJ-53718678 500 mg
Drug: JNJ-53718678 80 mg
Drug: Placebo

First Posted Date: 2017-12-20

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 72

Registration Number: NCT03379675

Locations: 🇧🇪
CHU Saint-Pierre, Bruxelles, Belgium
🇧🇪
Jaak Mortelmans, Ham, Belgium
🇧🇪
BVBA Dr. Luc Capiau, Massemen, Belgium

and more 121 locations

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection

Phase 3

Terminated

Conditions: Influenza A

Interventions: Drug: Pimodivir 600 mg
Drug: Placebo
Other: SOC Treatment

First Posted Date: 2017-12-18

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 334

Registration Number: NCT03376321

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇧🇬
Military Medical Academy - Sofia, Sofia, Bulgaria
🇧🇬
MHAT Dr Stefan Cherkezov, Veliko Tarnovo, Bulgaria

and more 263 locations

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: JNJ-63733657
Drug: Placebo

First Posted Date: 2017-12-18

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 72

Registration Number: NCT03375697

Locations: 🇩🇪
Klinik für Neurodegenerative Erkrankungen und Gerontopsychiatrie, Bonn, Germany
🇩🇪
CTC North GmbH & Co. KG, Hamburg, Germany
🇪🇸
Hosp. Clinico San Carlos, Madrid, Spain

and more 4 locations

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

Phase 2

Completed

Conditions: Insomnia Disorders

Interventions: Drug: Placebo
Drug: JNJ-42847922, 5 mg
Drug: JNJ-42847922, 20 mg
Drug: JNJ-42847922, 10 mg
Drug: Zolpidem

First Posted Date: 2017-12-15

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 365

Registration Number: NCT03375203

Locations: 🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States
🇺🇸
Sarkis Clinical Trials, Lake City, Florida, United States
🇺🇸
Suncoast Research Group, Miami, Florida, United States

and more 52 locations

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Phase 1

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: JNJ-42847922 20mg
Drug: JNJ-42847922 40mg
Drug: Placebo

First Posted Date: 2017-12-15

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 140

Registration Number: NCT03374475

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
🇧🇪
SGS Phase 1 Unit AZ St-Maarten, Mechelen, Belgium
🇺🇸
Qps-Mra, Llc, Miami, Florida, United States

and more 8 locations

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

Phase 1

Terminated

Conditions: Adenocarcinoma of Lung

Interventions: Biological: JNJ-64041757
Drug: Nivolumab

First Posted Date: 2017-12-13

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT03371381

Locations: 🇺🇸
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Medical Oncology Associates, PS, Spokane, Washington, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy